Abstract CT126: A phase I first time in human study to evaluate the safety, pharmacokinetics, and immunogenicity of MEDI5083 alone and in combination with durvalumab in selected advanced solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct126
Abstract: Background CD40 is a member of the TNFR superfamily that is broadly expressed by immune, vascular, epithelial, and tumor cells. Interaction between CD40 and its ligand CD40L plays an important role in innate and adaptive… read more here.
Keywords: combination; phase first; durvalumab; safety ... See more keywords
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps1113
Abstract: TPS1113 Background: PARP inhibition (PARPi) with olaparib is approved in HER2-negative germline BRCA mutant (g BRCAm) metastatic breast cancer. Maintenance PARPi in relapsed platinum-sensitive ovarian cancer improves median PFS regardless of gBRCA mutation status. Preclinical… read more here.
Keywords: platinum; breast cancer; maintenance; combination durvalumab ... See more keywords
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3003
Abstract: 3003Background: We report safety and tolerability of MEDI0562, a humanized IgG1κ OX40 monoclonal antibody (mAb), in combination with durvalumab (durva; anti-PD-L1 mAb) or tremelimumab (treme; anti-... read more here.
Keywords: safety tolerability; tolerability medi0562; combination durvalumab;
A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16599
Abstract: e16599Background: VEGFR TKIs and checkpoint inhibitors are current standards of care in HCC as single agents, however treatment options are limited, and significant unmet need remains. A recent ph3... read more here.
Keywords: phase open; tivozanib combination; study tivozanib; combination durvalumab ... See more keywords